Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes: case-cohort study within the PREDIMED Trial
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes : case-cohort study within the PREDIMED Trial. / Ruiz-Canela, Miguel; Guasch-Ferré, Marta; Toledo, Estefanía; Clish, Clary B.; Razquin, Cristina; Liang, Liming; Wang, Dong D.; Corella, Dolores; Estruch, Ramón; Hernáez, Álvaro; Yu, Edward; Gómez-Gracia, Enrique; Zheng, Yan; Arós, Fernando; Romaguera, Dora; Dennis, Courtney; Ros, Emilio; Lapetra, José; Serra-Majem, Lluis; Papandreou, Christopher; Portoles, Olga; Fitó, Montserrat; Salas-Salvadó, Jordi; Hu, Frank B.; Martínez-González, Miguel A.
In: Diabetologia, Vol. 61, No. 7, 2018, p. 1560-1571.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Plasma branched chain/aromatic amino acids, enriched Mediterranean diet and risk of type 2 diabetes
T2 - case-cohort study within the PREDIMED Trial
AU - Ruiz-Canela, Miguel
AU - Guasch-Ferré, Marta
AU - Toledo, Estefanía
AU - Clish, Clary B.
AU - Razquin, Cristina
AU - Liang, Liming
AU - Wang, Dong D.
AU - Corella, Dolores
AU - Estruch, Ramón
AU - Hernáez, Álvaro
AU - Yu, Edward
AU - Gómez-Gracia, Enrique
AU - Zheng, Yan
AU - Arós, Fernando
AU - Romaguera, Dora
AU - Dennis, Courtney
AU - Ros, Emilio
AU - Lapetra, José
AU - Serra-Majem, Lluis
AU - Papandreou, Christopher
AU - Portoles, Olga
AU - Fitó, Montserrat
AU - Salas-Salvadó, Jordi
AU - Hu, Frank B.
AU - Martínez-González, Miguel A.
N1 - Publisher Copyright: © 2018, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2018
Y1 - 2018
N2 - Aims/hypothesis: Branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs) are associated with type 2 diabetes. However, repeated measurements of BCAA/AAA and their interactions with dietary interventions have not been evaluated. We investigated the associations between baseline and changes at 1 year in BCAA/AAA with type 2 diabetes in the context of a Mediterranean diet (MedDiet) trial. Methods: We included 251 participants with incident type 2 diabetes and a random sample of 694 participants (641 participants without type 2 diabetes and 53 overlapping cases) in a case-cohort study nested within the PREvención con DIeta MEDiterránea (PREDIMED) trial. Participants were randomised to a MedDiet+extra-virgin olive oil (n = 273), a MedDiet+nuts (n = 324) or a control diet (n = 295). We used LC-MS/MS to measure plasma levels of amino acids. Type 2 diabetes was a pre-specified secondary outcome of the PREDIMED trial. Results: Elevated plasma levels of individual BCAAs/AAAs were associated with higher type 2 diabetes risk after a median follow-up of 3.8 years: multivariable HR for the highest vs lowest quartile ranged from 1.32 for phenylalanine ([95% CI 0.90, 1.92], p for trend = 0.015) to 3.29 for leucine ([95% CI 2.03, 5.34], p for trend<0.001). Increases in BCAA score at 1 year were associated with higher type 2 diabetes risk in the control group with HR per SD = 1.61 (95% CI 1.02, 2.54), but not in the MedDiet groups (p for interaction <0.001). The MedDiet+extra-virgin olive oil significantly reduced BCAA levels after 1 year of intervention (p = 0.005 vs the control group). Conclusions/interpretation: Our results support that higher baseline BCAAs and their increases at 1 year were associated with higher type 2 diabetes risk. A Mediterranean diet rich in extra-virgin olive oil significantly reduced the levels of BCAA and attenuated the positive association between plasma BCAA levels and type 2 diabetes incidence. Clinical trial number: SRCTN35739639 (www.controlled-trials.com).
AB - Aims/hypothesis: Branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs) are associated with type 2 diabetes. However, repeated measurements of BCAA/AAA and their interactions with dietary interventions have not been evaluated. We investigated the associations between baseline and changes at 1 year in BCAA/AAA with type 2 diabetes in the context of a Mediterranean diet (MedDiet) trial. Methods: We included 251 participants with incident type 2 diabetes and a random sample of 694 participants (641 participants without type 2 diabetes and 53 overlapping cases) in a case-cohort study nested within the PREvención con DIeta MEDiterránea (PREDIMED) trial. Participants were randomised to a MedDiet+extra-virgin olive oil (n = 273), a MedDiet+nuts (n = 324) or a control diet (n = 295). We used LC-MS/MS to measure plasma levels of amino acids. Type 2 diabetes was a pre-specified secondary outcome of the PREDIMED trial. Results: Elevated plasma levels of individual BCAAs/AAAs were associated with higher type 2 diabetes risk after a median follow-up of 3.8 years: multivariable HR for the highest vs lowest quartile ranged from 1.32 for phenylalanine ([95% CI 0.90, 1.92], p for trend = 0.015) to 3.29 for leucine ([95% CI 2.03, 5.34], p for trend<0.001). Increases in BCAA score at 1 year were associated with higher type 2 diabetes risk in the control group with HR per SD = 1.61 (95% CI 1.02, 2.54), but not in the MedDiet groups (p for interaction <0.001). The MedDiet+extra-virgin olive oil significantly reduced BCAA levels after 1 year of intervention (p = 0.005 vs the control group). Conclusions/interpretation: Our results support that higher baseline BCAAs and their increases at 1 year were associated with higher type 2 diabetes risk. A Mediterranean diet rich in extra-virgin olive oil significantly reduced the levels of BCAA and attenuated the positive association between plasma BCAA levels and type 2 diabetes incidence. Clinical trial number: SRCTN35739639 (www.controlled-trials.com).
KW - Aromatic amino acids
KW - Branched-chain amino acids
KW - Mediterranean diet
KW - Type 2 diabetes
U2 - 10.1007/s00125-018-4611-5
DO - 10.1007/s00125-018-4611-5
M3 - Journal article
C2 - 29663011
AN - SCOPUS:85045441217
VL - 61
SP - 1560
EP - 1571
JO - Diabetologia
JF - Diabetologia
SN - 0012-186X
IS - 7
ER -
ID: 358106341